End Stage Kidney Disease patient undergoing Hemodialysis. End stage renal disease
Conditions
Interventions
Intervention 1: Intervention group 1: This group will receive a half dose of injection taurolockHEP500® into the lumens of the tunnelled catheter after each dialysis session for three months. Interven
Sponsors
Armed Forces Institute Of Urology Rawalpindi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who were undergoing hemodialysis via a tunneled double lumen catheter with blood flow rate (BFR) of > 250 mL/min at the start of the study No previous history of catheter related blood stream infection
Exclusion criteria
Exclusion criteria: Patients allergic to used drugs(TaurolockHEP500®) IV drug abusers Changing dialysis from catheter to AVF
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood flow rate. Timepoint: Blood flow rate during each session of hemodialysis. Method of measurement: Blood flow rate checked during hemodialysis from blood pump of dialysis machine.;Blood culture for identifying infection. Timepoint: The blood sample will be collected if patients develops fever or shivering during or within 4 hours after hemodialysis session. Method of measurement: The blood will be drawn from venous circulation by using strile blood sample collecting syringes. The collected sample will be transferred to and preserved in blood sample bottles. | — |
Countries
Pakistan
Contacts
Public ContactGhulam Mustafa
Armed Forces Institute Of Urology Rawalpindi
Outcome results
None listed